Enzon Pharmaceuticals, INC 8-K filings

Viskase Holdings, Inc. entered into a Seventh Amendment to its credit agreement, extending the maturity date to August 2027 and adjusting interest rates.

Viskase Holdings, Inc. has appointed Grant Thornton LLP as its new independent registered public accounting firm following its recent merger.

Viskase Holdings, Inc. has appointed Michael Blecic as Chief Financial Officer and Joseph D. King as Executive Vice President.

Enzon Pharmaceuticals, Inc. has completed its merger with Viskase Companies, Inc., rebranding as Viskase Holdings, Inc. and focusing on the combined entity's core business.

Enzon Pharmaceuticals, Inc. announced the completion of its exchange offer for Series C Non-Convertible Redeemable Preferred Stock.

Enzon Pharmaceuticals, Inc. announced a 1-for-100 reverse stock split effective March 24, 2026, and extended its Section 382 Rights Agreement to March 26, 2026, in preparation for its merger with Viskase Companies, Inc.

Enzon Pharmaceuticals, Inc. announced its tenth amendment to the Section 382 Rights Agreement, extending its expiration date to March 24, 2026, to protect valuable tax assets.

Enzon Pharmaceuticals, Inc. announced an extension to its exchange offer for Series C Preferred Stock as part of its proposed merger with Viskase Companies, Inc.

Enzon Pharmaceuticals announced the eighth amendment to its Section 382 Rights Agreement and an extension of its Series C Preferred Stock exchange offer, both related to its proposed merger with Viskase.

Enzon Pharmaceuticals, Inc. stockholders have approved a 1-for-100 reverse stock split and the merger agreement with Viskase Companies, Inc.

Enzon Pharmaceuticals, Inc. announced the extension of its Section 382 Rights Agreement to March 2, 2026, a measure designed to protect its valuable tax assets.

Enzon Pharmaceuticals, Inc. announced the sixth amendment to its Section 382 Rights Agreement, extending the final expiration date to January 31, 2026, to protect its tax benefits.

Enzon Pharmaceuticals and Viskase Companies have amended their merger agreement, granting Viskase stockholders 55% ownership of the combined entity and extending the closing deadline.

Enzon Pharmaceuticals, Inc. has extended its Section 382 Rights Agreement to December 31, 2025, to protect valuable tax assets.

Enzon Pharmaceuticals, Inc. and Viskase Companies, Inc. have entered into a definitive merger agreement, creating Viskase Holdings, Inc. in an all-stock transaction where Viskase stockholders will own approximately 84.1% of the combined entity.

Enzon Pharmaceuticals extends its Section 382 Rights Agreement to June 30, 2026, aiming to preserve potential tax benefits.

Enzon Pharmaceuticals has appointed a new director, Stephen T. Wills, and formed a special committee to assess a potential transaction proposed by Viskase Companies, Inc.

Enzon Pharmaceuticals has declared a 3% cash dividend for its Series C Non-Convertible Redeemable Preferred Stock, totaling $1,274,400.

Enzon Pharmaceuticals successfully held its 2024 annual meeting, electing three directors, ratifying the appointment of its accounting firm, approving executive compensation, and extending the expiration date of its Rights Agreement.

Enzon Pharmaceuticals has amended its previous 8-K filing to clarify the record date for its 2024 Annual Meeting of Stockholders, which is now set for August 7, 2024.

Enzon Pharmaceuticals has announced the date for its 2024 Annual Meeting of Stockholders and the deadlines for shareholder proposals and director nominations.

Enzon Pharmaceuticals has successfully regained compliance with OTCQX listing standards after its stock price traded above $0.10 for the required period.

Enzon Pharmaceuticals has extended the expiration date of its shareholder rights agreement to March 31, 2025, to protect its tax benefits.